# Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization

> **NCT05264974** · PHASE1 · RECRUITING · sponsor: **University of Florida** · enrollment: 18 (estimated)

## Conditions studied

- Melanoma
- Soft Tissue Sarcoma

## Interventions

- **BIOLOGICAL:** Autologous total tumor mRNA loaded DOTAP liposome vaccine

## Key facts

- **NCT ID:** NCT05264974
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-17
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05264974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05264974, "Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT05264974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*